AIM ImmunoTech AIM
NYSE AIM
$0.18 -0.01 (-5.26%)
At close: Oct 2, 2026 · 4:00 PM EDT

AIM ImmunoTech (AIM) Gains from Sales and Divestitures (2018 - 2023)

Updated

AIM ImmunoTech (AIM) recorded Gains from Sales and Divestitures of $2,000 in Q4 2023, down 94.9% from the prior quarter.

Analysis

AIM ImmunoTech (AIM) Gains from Sales and Divestitures (2018 - 2023) Analysis & Trends

For FY2023, AIM ImmunoTech reported Gains from Sales and Divestitures of $18,000, up 500.0% from FY2022.

  • Annual Gains from Sales and Divestitures has a five-year compound annual growth rate of -39.6% (FY2018 to FY2023).
  • Across earlier years, Gains from Sales and Divestitures came in at $3,000 in FY2022 (-98.6%) and $216,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 AIM ImmunoTech 3.08 Mn -18.22 Mn 21,000.00
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 2,000.00
Sep 30, 2023 39,000.00
Mar 31, 2023 -23,000.00
Mar 31, 2018 223,000.00
API Access

AIM ImmunoTech Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=AIM&period=max&api_key=YOUR_API_KEY